Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Nov 2009

Quintás-Cardama Alfonso, Kantarjian Hagop, Manshouri Taghi, Luthra Rajyalakshmi, Estrov Zeev, Pierce Sherry, Richie Mary Ann, Borthakur Gautam, Konopleva Marina, Cortes Jorge, Verstovsek Srdan

Abstract excerpt

PURPOSE: We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV). PATIENTS AND METHODS: Seventy-nine patients (40 with PV and 39 with ET) have been treated. Median time from diagnosis to PEG-IFN-alpha-2a was 54 months in patients with PV and 33 months in patients with ET. Eighty-one percent of patients had received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Neutropenia

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 19826111
DOI: 10.1200/JCO.2009.23.6075
PMCID: PMC4881362

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.PMID 19826111Read ↗

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burdenSemantic proximity Read ↗

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.